These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25624778)

  • 21. CD44(high)CD24(low) molecular signature determines the Cancer Stem Cell and EMT phenotype in Oral Squamous Cell Carcinoma.
    Ghuwalewala S; Ghatak D; Das P; Dey S; Sarkar S; Alam N; Panda CK; Roychoudhury S
    Stem Cell Res; 2016 Mar; 16(2):405-17. PubMed ID: 26926234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High GD2 expression defines breast cancer cells with enhanced invasiveness.
    Mansoori M; Roudi R; Abbasi A; Abolhasani M; Abdi Rad I; Shariftabrizi A; Madjd Z
    Exp Mol Pathol; 2019 Aug; 109():25-35. PubMed ID: 31075227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
    Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
    Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
    de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
    J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of SDF-1 activates the NF-κB pathway to induce epithelial to mesenchymal transition and cancer stem cell-like phenotypes of breast cancer cells.
    Kong L; Guo S; Liu C; Zhao Y; Feng C; Liu Y; Wang T; Li C
    Int J Oncol; 2016 Mar; 48(3):1085-94. PubMed ID: 26782945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD44 and CD24 coordinate the reprogramming of nasopharyngeal carcinoma cells towards a cancer stem cell phenotype through STAT3 activation.
    Shen YA; Wang CY; Chuang HY; Hwang JJ; Chi WH; Shu CH; Ho CY; Li WY; Chen YJ
    Oncotarget; 2016 Sep; 7(36):58351-58366. PubMed ID: 27521216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
    Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
    J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of cancer stem cells from different grades of human colorectal cancer.
    Manhas J; Bhattacharya A; Agrawal SK; Gupta B; Das P; Deo SV; Pal S; Sen S
    Tumour Biol; 2016 Oct; 37(10):14069-14081. PubMed ID: 27507615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
    Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
    Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Telomerase reverse transcriptase coordinates with the epithelial-to-mesenchymal transition through a feedback loop to define properties of breast cancer stem cells.
    El-Badawy A; Ghoneim NI; Nasr MA; Elkhenany H; Ahmed TA; Ahmed SM; El-Badri N
    Biol Open; 2018 Jul; 7(7):. PubMed ID: 29907642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Features of CD44+/CD24-low phenotypic cell distribution in relation to predictive markers and molecular subtypes of invasive ductal carcinoma of the breast.
    Gudadze M; Kankava Q; Mariamidze A; Burkadze G
    Georgian Med News; 2014 Mar; (228):81-7. PubMed ID: 24743129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast cancer stem cells expressing different stem cell markers exhibit distinct biological characteristics.
    Shao J; Fan W; Ma B; Wu Y
    Mol Med Rep; 2016 Dec; 14(6):4991-4998. PubMed ID: 27840965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma.
    Mohamed SY; Kaf RM; Ahmed MM; Elwan A; Ashour HR; Ibrahim A
    J Gastrointest Cancer; 2019 Dec; 50(4):824-837. PubMed ID: 30136202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer.
    West NR; Murray JI; Watson PH
    Oncogene; 2014 Mar; 33(12):1485-94. PubMed ID: 23584474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epithelial cell adhesion molecule and epithelial-mesenchymal transition are associated with vasculogenic mimicry, poor prognosis, and metastasis of triple negative breast cancer.
    Wu Q; Wang J; Liu Y; Gong X
    Int J Clin Exp Pathol; 2019; 12(5):1678-1689. PubMed ID: 31933986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
    Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
    Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aggressive Phenotype of Cells Disseminated via Hematogenous and Lymphatic Route in Breast Cancer Patients.
    Markiewicz A; Nagel A; Szade J; Majewska H; Skokowski J; Seroczynska B; Stokowy T; Welnicka-Jaskiewicz M; Zaczek AJ
    Transl Oncol; 2018 Jun; 11(3):722-731. PubMed ID: 29660692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD44
    Wang H; Wang L; Song Y; Wang S; Huang X; Xuan Q; Kang X; Zhang Q
    Oncol Lett; 2017 Nov; 14(5):5890-5898. PubMed ID: 29113223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA-34a regulates epithelial-mesenchymal transition and cancer stem cell phenotype of head and neck squamous cell carcinoma in vitro.
    Sun Z; Hu W; Xu J; Kaufmann AM; Albers AE
    Int J Oncol; 2015 Oct; 47(4):1339-50. PubMed ID: 26323460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
    Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
    Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.